VivoSeq
Other

Pyoderma

12

Pipeline Programs↗

0

Active Trials↗

8

Companies Involved↗

Pyoderma is an emerging landscape with 12 programs across 8 companies. The most active players are SWISS BIOPHARMA MED GmbH, Novartis, Eli Lilly. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SWISS BIOPHARMA MED GmbH

1 program

Phase 1Novartis logo

Novartis

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

12programs
Small molecule758%
Monoclonal antibody542%

Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Withdrawn1 · 33%

Clinical Trials

Trial Activity

Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
Completed·SSWISS BIOPHARMA MED GmbH·Phase 1·NCT04895566·10 enrolled
Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma
Completed·VValenta Pharm JSC·Phase 3·NCT05561816·240 enrolled
Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)
Withdrawn·Merck & Co. logoMerck & Co.·Phase 4·NCT00202891

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)